Skip to main content
Top
Published in: Clinical Reviews in Allergy & Immunology 1/2010

01-02-2010

Pathogenesis of Hyper IgE Syndrome

Authors: Jennifer Heimall, Alexandra Freeman, Steven M. Holland

Published in: Clinical Reviews in Allergy & Immunology | Issue 1/2010

Login to get access

Abstract

Hyper IgE syndrome (HIES) is a rare primary immunodeficiency characterized by the triad of elevated IgE and eosinophilia, eczema, and recurrent skin and pulmonary infections. The autosomal dominant (AD) form of HIES results from mutations in STAT3 and is characterized by disordered inflammation, connective tissue, and skeletal abnormalities. Tissue-specific STAT3 deficiency in animals, cytokine and transcriptional array data, and careful clinical phenotyping have explained some of the pathophysiology of the immunologic and non-immunologic abnormalities of AD-HIES. In depth study of the role of STAT3 mutations in specific aspects of HIES may lead to better understanding and new approaches to treatment of conditions intrinsic to HIES that are common in the general population, such as staphylococcal infections, scoliosis, osteoporosis, bronchiectasis, and arterial aneurysms. As the genotypes of STAT3 deficiency are further characterized, genotype–phenotype correlations may emerge that will be informative regarding specific molecular interactions. Autosomal recessive forms of hyper IgE (AR-HIES) have also been reported. A single case of homozygous deficiency of the signal protein Tyk2 has been reported as well as a recessive syndrome with some features overlapping AD-HIES, but for which the genetic etiology is unknown. Better understanding of the pathophysiology and mechanisms of dominant and recessive hyper IgE syndromes will shed light on somatic and immune biology and may improve quality of life and survival for HIES patients.
Literature
1.
go back to reference Buckley RH, Wray BB, Belmaker EZ (1972) Extreme hyperimmunologlobulinemia E and undue susceptibility to infection. Pediatrics 49:59–70PubMed Buckley RH, Wray BB, Belmaker EZ (1972) Extreme hyperimmunologlobulinemia E and undue susceptibility to infection. Pediatrics 49:59–70PubMed
2.
go back to reference Davis SD, Wedgwood RJ (1966) Job’s syndrome: recurrent, “cold”, staphylococcal abscesses. Lancet 1:1013–1015CrossRefPubMed Davis SD, Wedgwood RJ (1966) Job’s syndrome: recurrent, “cold”, staphylococcal abscesses. Lancet 1:1013–1015CrossRefPubMed
4.
go back to reference Grimbacher B, Holland SM, Gallin JI et al (1999) Hyper-IgE syndrome with recurrent infections—an autosomal dominant multisystem disorder. N. Engl J Med 340:692–702CrossRefPubMed Grimbacher B, Holland SM, Gallin JI et al (1999) Hyper-IgE syndrome with recurrent infections—an autosomal dominant multisystem disorder. N. Engl J Med 340:692–702CrossRefPubMed
5.
go back to reference Holland S, DeLeo F, Elloumi H et al (2007) STAT3 mutations in the hyper-IgE syndrome. NEJM 357(16):1608–1619CrossRefPubMed Holland S, DeLeo F, Elloumi H et al (2007) STAT3 mutations in the hyper-IgE syndrome. NEJM 357(16):1608–1619CrossRefPubMed
6.
go back to reference Minegishi Y, Saito M, Tsuchiya S (2007) Dominant negative mutations in the DNA binding domain of STAT3 cause hyper-IgE syndrome. Nature 448:1058–1062CrossRefPubMed Minegishi Y, Saito M, Tsuchiya S (2007) Dominant negative mutations in the DNA binding domain of STAT3 cause hyper-IgE syndrome. Nature 448:1058–1062CrossRefPubMed
7.
go back to reference Freeman A, Kleiner D, Nadiminti H et al (2007) Causes of death in hyper IgE syndrome. JACI 119:1234–1240 Freeman A, Kleiner D, Nadiminti H et al (2007) Causes of death in hyper IgE syndrome. JACI 119:1234–1240
8.
go back to reference Chamlin SL, McCalmont TH, Cunningham BB, Esterly NB, Lai CH et al (2002) Cutaneous manifestations of hyper-IgE syndrome in infants and children. J Pediatr 141:572–575CrossRefPubMed Chamlin SL, McCalmont TH, Cunningham BB, Esterly NB, Lai CH et al (2002) Cutaneous manifestations of hyper-IgE syndrome in infants and children. J Pediatr 141:572–575CrossRefPubMed
9.
go back to reference Eberting CL, Davis J, Puck JM, Holland SM (2004) Dermatitis and the newborn rash of hyper-IgE syndrome. Arch Dermatol 140:1119–1125CrossRefPubMed Eberting CL, Davis J, Puck JM, Holland SM (2004) Dermatitis and the newborn rash of hyper-IgE syndrome. Arch Dermatol 140:1119–1125CrossRefPubMed
10.
go back to reference Freeman AF, Davis J, Anderson VL, Barson W, Darnell DN, Puck JM, Holland SM (2006) Pneumocystis jiroveci infection in patients with hyper-immunoglobulin E syndrome. Pediatrics 118:e1271–e1275CrossRefPubMed Freeman AF, Davis J, Anderson VL, Barson W, Darnell DN, Puck JM, Holland SM (2006) Pneumocystis jiroveci infection in patients with hyper-immunoglobulin E syndrome. Pediatrics 118:e1271–e1275CrossRefPubMed
11.
go back to reference Hutto JO, Bryan CS, Greene FL, White CJ, Gallin JL (1988) Cryptococcosis of the colon resembling Crohn’s disease in a patient with the hyperimmunoglobulinemia E syndrome. Gastroenterology 94:808–812PubMed Hutto JO, Bryan CS, Greene FL, White CJ, Gallin JL (1988) Cryptococcosis of the colon resembling Crohn’s disease in a patient with the hyperimmunoglobulinemia E syndrome. Gastroenterology 94:808–812PubMed
12.
go back to reference Jacobs DH, Macher AM, Handler R, Bennett JE, Collen MJ, Gallin JI (1984) Esophageal cryptococcosis in a patient with the hyperimmunoglobulin E-recurrent infection (Job’s) syndrome. Gastroenterology 87:201–203PubMed Jacobs DH, Macher AM, Handler R, Bennett JE, Collen MJ, Gallin JI (1984) Esophageal cryptococcosis in a patient with the hyperimmunoglobulin E-recurrent infection (Job’s) syndrome. Gastroenterology 87:201–203PubMed
13.
go back to reference Domingo D, Freeman AF, Davis J, Puck JM, Tianxia W, Holland SM, Hart TC (2007) Novel intraoral phenotypes in hyper Immunoglobulin E syndrome. Oral Diseases 14:73–81 Domingo D, Freeman AF, Davis J, Puck JM, Tianxia W, Holland SM, Hart TC (2007) Novel intraoral phenotypes in hyper Immunoglobulin E syndrome. Oral Diseases 14:73–81
14.
go back to reference O’Connell AC, Puck JM, Grimbacher B, Facchetti F, Majorana A, Gallin JI, Malech HL, Holland SM (2000) Delayed eruption of permanent teeth in hyperimmunoglobulinemia E recurrent infection syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 89:177–185CrossRefPubMed O’Connell AC, Puck JM, Grimbacher B, Facchetti F, Majorana A, Gallin JI, Malech HL, Holland SM (2000) Delayed eruption of permanent teeth in hyperimmunoglobulinemia E recurrent infection syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 89:177–185CrossRefPubMed
15.
go back to reference Ling JC, Freeman AF, Gharib AM, Arai AE, Lederman RJ, Rosing DR, Holland SM (2007) Coronary artery aneurysms in patients with hyper IgE recurrent infection syndrome. Clin Immunol 122:255–258CrossRefPubMed Ling JC, Freeman AF, Gharib AM, Arai AE, Lederman RJ, Rosing DR, Holland SM (2007) Coronary artery aneurysms in patients with hyper IgE recurrent infection syndrome. Clin Immunol 122:255–258CrossRefPubMed
16.
go back to reference Young TY, Jerome D, Gupta S (2007) Hyperimmunoglobulinemia E syndrome associated with coronary artery aneurysms: deficiency of central memory CD4+ T cells and expansion of effector memory CD4+ T cells. Ann Allergy Asthma Immunol 98:389–392PubMedCrossRef Young TY, Jerome D, Gupta S (2007) Hyperimmunoglobulinemia E syndrome associated with coronary artery aneurysms: deficiency of central memory CD4+ T cells and expansion of effector memory CD4+ T cells. Ann Allergy Asthma Immunol 98:389–392PubMedCrossRef
17.
go back to reference Freeman AF, Collura-Burke CJ, Patronas NJ, Ilcus LS, Darnell D, Davis J, Puck JM, Holland SM (2007) Brain abnormalities in patients with hyperimmunoglobulin E syndrome. Pediatrics 119:e1121–e1125CrossRefPubMed Freeman AF, Collura-Burke CJ, Patronas NJ, Ilcus LS, Darnell D, Davis J, Puck JM, Holland SM (2007) Brain abnormalities in patients with hyperimmunoglobulin E syndrome. Pediatrics 119:e1121–e1125CrossRefPubMed
18.
go back to reference Hoger PH, Boltshauser E, Hitzig WH (1985) Craniosynostosis in hyper-IgE syndrome. Eur J Pediatr 144:414–417CrossRefPubMed Hoger PH, Boltshauser E, Hitzig WH (1985) Craniosynostosis in hyper-IgE syndrome. Eur J Pediatr 144:414–417CrossRefPubMed
19.
go back to reference Smithwick EM, Finelt M, Pahwa S, Good RA, Naspitz CK, Mendes NF et al (1978) Cranial synostosis in Job’s syndrome. Lancet 15:826CrossRef Smithwick EM, Finelt M, Pahwa S, Good RA, Naspitz CK, Mendes NF et al (1978) Cranial synostosis in Job’s syndrome. Lancet 15:826CrossRef
20.
go back to reference Grimbacher B, Schaffer AA, Holland SM, Davis J, Gallin JI, Malech HL, Atkinson TP, Belohradksy BH, Buckley RH, Cossu F, Espanol T, Garty BZ, Metamoros N, Myers LA, Nelson RP, Ochs HD, Renner ED, Wellinghausen N, Puck JM (1999) Genetic linkage of hyper-IgE syndrome to chromosome 4. Am J Hum Genet 65:735–744CrossRefPubMed Grimbacher B, Schaffer AA, Holland SM, Davis J, Gallin JI, Malech HL, Atkinson TP, Belohradksy BH, Buckley RH, Cossu F, Espanol T, Garty BZ, Metamoros N, Myers LA, Nelson RP, Ochs HD, Renner ED, Wellinghausen N, Puck JM (1999) Genetic linkage of hyper-IgE syndrome to chromosome 4. Am J Hum Genet 65:735–744CrossRefPubMed
21.
go back to reference Leonard GD, Posadas E, Herrmann PC et al (2004) Non-Hodgkin’s lymphoma in Job’s syndrome: a case report and review of the literature. Leuk Lymphoma 45:2521–2525CrossRefPubMed Leonard GD, Posadas E, Herrmann PC et al (2004) Non-Hodgkin’s lymphoma in Job’s syndrome: a case report and review of the literature. Leuk Lymphoma 45:2521–2525CrossRefPubMed
22.
go back to reference Levy DE, Lee C (2002) What does Stat3 do? J Clin Invest 109:1143–1148PubMed Levy DE, Lee C (2002) What does Stat3 do? J Clin Invest 109:1143–1148PubMed
23.
go back to reference Renner E, Rylaarsdam S, Anover-Sombke S et al (2008) Novel signal transducer and activator of transcription 3 mutations, reduced Th17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome. JACI 122:181–187 Renner E, Rylaarsdam S, Anover-Sombke S et al (2008) Novel signal transducer and activator of transcription 3 mutations, reduced Th17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome. JACI 122:181–187
24.
go back to reference Borish L, Steinke J (2003) Cytokines and chemokines. JACI 111:S460–S475 Borish L, Steinke J (2003) Cytokines and chemokines. JACI 111:S460–S475
25.
go back to reference Commins S, Steinke J, Borish L (2008) The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, IL-29. JACI 121(5):1108–1111 Commins S, Steinke J, Borish L (2008) The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, IL-29. JACI 121(5):1108–1111
26.
go back to reference Milner J, Brenchley J, Laurence A et al (2008) Impaired Th17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 252:773–776 This is the first study to demonstrate that persons with HIES lack IL17-producing T cells and that their T cells are unable to be differentiated to produce Th17 cells in vitroCrossRef Milner J, Brenchley J, Laurence A et al (2008) Impaired Th17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 252:773–776 This is the first study to demonstrate that persons with HIES lack IL17-producing T cells and that their T cells are unable to be differentiated to produce Th17 cells in vitroCrossRef
27.
go back to reference Beaucoudrey L, Puel A, Filpe-Santos O et al (2008) Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing cells. J Exp Med 205:1543–1550CrossRefPubMed Beaucoudrey L, Puel A, Filpe-Santos O et al (2008) Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing cells. J Exp Med 205:1543–1550CrossRefPubMed
28.
go back to reference Harris T, Grosso J, Yen H et al (2007) An in vivo requirement for STAT3 signaling in Th17 development and Th17 dependant autoimmunity. J Immunol 179:4313–4317PubMed Harris T, Grosso J, Yen H et al (2007) An in vivo requirement for STAT3 signaling in Th17 development and Th17 dependant autoimmunity. J Immunol 179:4313–4317PubMed
29.
go back to reference Ma C, Chew G, Simpson N et al (2008) Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J Exp Med 205:1551–1557CrossRefPubMed Ma C, Chew G, Simpson N et al (2008) Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J Exp Med 205:1551–1557CrossRefPubMed
30.
go back to reference Aujla SH, Chan YR, Zheng M et al (2008) IL-22 mediates mucosal host defense against gram-negative bacterial pneumonia. Nat Med 14:275–281CrossRefPubMed Aujla SH, Chan YR, Zheng M et al (2008) IL-22 mediates mucosal host defense against gram-negative bacterial pneumonia. Nat Med 14:275–281CrossRefPubMed
31.
go back to reference Dong C (2008) Th17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol 8:337–348CrossRefPubMed Dong C (2008) Th17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol 8:337–348CrossRefPubMed
32.
go back to reference Huang W, Na L, Fidel PL, Schwarzenberger P (2004) Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J Infect Dis 190:624–631CrossRefPubMed Huang W, Na L, Fidel PL, Schwarzenberger P (2004) Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J Infect Dis 190:624–631CrossRefPubMed
33.
go back to reference Kao CY, Chen Y, Thai P et al (2004) IL-17 markedly up-regulates Beta-defensin-2 expression in human airway epithelium via JAK and NF-kB signaling pathways. J Immunol 173:3482–3491PubMed Kao CY, Chen Y, Thai P et al (2004) IL-17 markedly up-regulates Beta-defensin-2 expression in human airway epithelium via JAK and NF-kB signaling pathways. J Immunol 173:3482–3491PubMed
34.
go back to reference Schnyder-Candrian S et al (2006) Interleukin-17 is a negative regulator of established allergic asthma. J Exp Med 203:2715–2725CrossRefPubMed Schnyder-Candrian S et al (2006) Interleukin-17 is a negative regulator of established allergic asthma. J Exp Med 203:2715–2725CrossRefPubMed
35.
go back to reference Ozaki K et al (2002) A critical role for IL-21 in regulating immunoglobulin production. Science 298:1630–1634CrossRefPubMed Ozaki K et al (2002) A critical role for IL-21 in regulating immunoglobulin production. Science 298:1630–1634CrossRefPubMed
36.
go back to reference Avery D, Ma C, Bryant V et al (2008) STAT3 is required for IL-21 induced secretion of IgE from human naïve B cells. Blood 112:1784–1793CrossRefPubMed Avery D, Ma C, Bryant V et al (2008) STAT3 is required for IL-21 induced secretion of IgE from human naïve B cells. Blood 112:1784–1793CrossRefPubMed
37.
go back to reference Wolk K, Kunz S, Witte E et al (2004) IL-22 increases the innate immunity of tissues. Immunity 21:241–254CrossRefPubMed Wolk K, Kunz S, Witte E et al (2004) IL-22 increases the innate immunity of tissues. Immunity 21:241–254CrossRefPubMed
38.
go back to reference Yeganeh M, Henneke P, Rezaei N et al (2008) Toll-like receptor stimulation induces higher TNF-a secretion in peripheral blood mononuclear cells from patients with hyper IgE syndrome. Int Arch Allergy Immunol 146:190–194CrossRefPubMed Yeganeh M, Henneke P, Rezaei N et al (2008) Toll-like receptor stimulation induces higher TNF-a secretion in peripheral blood mononuclear cells from patients with hyper IgE syndrome. Int Arch Allergy Immunol 146:190–194CrossRefPubMed
39.
go back to reference Takeda K, Clausen BE, Kaisho T et al (1999) Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10:39–49CrossRefPubMed Takeda K, Clausen BE, Kaisho T et al (1999) Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10:39–49CrossRefPubMed
40.
go back to reference Takeda K, Noguchi K, Shi W et al (1997) Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci U S A 94:3801–3804CrossRefPubMed Takeda K, Noguchi K, Shi W et al (1997) Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci U S A 94:3801–3804CrossRefPubMed
41.
go back to reference Hokuto I, Ikegami M, Yoshida M et al (2004) Stat-3 is required for pulmonary homeostasis during hyperoxia. J Clin Invest 113:28–37PubMed Hokuto I, Ikegami M, Yoshida M et al (2004) Stat-3 is required for pulmonary homeostasis during hyperoxia. J Clin Invest 113:28–37PubMed
42.
go back to reference Zhang A, Welte T, Troiano N et al (2005) Osteoporosis with increased osteoclastogenesis in hematopoietic cell-specific STAT3-deficient mice. Biochem Biophys Res Comm 328:800–807CrossRefPubMed Zhang A, Welte T, Troiano N et al (2005) Osteoporosis with increased osteoclastogenesis in hematopoietic cell-specific STAT3-deficient mice. Biochem Biophys Res Comm 328:800–807CrossRefPubMed
43.
go back to reference Leung DY, Key L, Steinberg JJ, Young MC, Von Deck M, Wilkinson R, Geha R (1988) Increased in vitro bone resorption by monocytes in the hyper-immunologulin E syndrome. J Immunol 140:84–88PubMed Leung DY, Key L, Steinberg JJ, Young MC, Von Deck M, Wilkinson R, Geha R (1988) Increased in vitro bone resorption by monocytes in the hyper-immunologulin E syndrome. J Immunol 140:84–88PubMed
44.
go back to reference Datta HK, Ng WF, Walker JA et al (2008) The cell biology of bone metabolism. J Clin Pathol 61:577–587CrossRefPubMed Datta HK, Ng WF, Walker JA et al (2008) The cell biology of bone metabolism. J Clin Pathol 61:577–587CrossRefPubMed
45.
go back to reference Duplomb L, Baud’huin M, Charrier C et al. (2008) IL-6 inhibits RANKL-induced osteoclastogenesis by diverting cells into the macrophage lineage: key role of Serine727 phosphorylation of STAT3. Endocrinology. doi:10.1210/en.2007-1719 Duplomb L, Baud’huin M, Charrier C et al. (2008) IL-6 inhibits RANKL-induced osteoclastogenesis by diverting cells into the macrophage lineage: key role of Serine727 phosphorylation of STAT3. Endocrinology. doi:10.​1210/​en.​2007-1719
46.
go back to reference Okada S, Nakamura M, Katoh H et al (2006) Conditional ablation of Stat3 or Socs3 discloses a dual role for reactive astrocytes after spinal cord injury. Nat Med 12:829–834CrossRefPubMed Okada S, Nakamura M, Katoh H et al (2006) Conditional ablation of Stat3 or Socs3 discloses a dual role for reactive astrocytes after spinal cord injury. Nat Med 12:829–834CrossRefPubMed
47.
go back to reference Hilfiker-Kleiner D, Hilfiker A, Fuchs M et al (2004) Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition and heart protection from ischemic injury. Circ Res 95(2):187–195CrossRefPubMed Hilfiker-Kleiner D, Hilfiker A, Fuchs M et al (2004) Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition and heart protection from ischemic injury. Circ Res 95(2):187–195CrossRefPubMed
48.
go back to reference Scarabelli T, Townsend P, Scarabelli C et al (2008) Amino acid supplementation differentially modulates STAT1 and STAT3 activation in the myocardium exposed to ischemia/reperfusion injury. Am J Cardiol 101:63E–68ECrossRefPubMed Scarabelli T, Townsend P, Scarabelli C et al (2008) Amino acid supplementation differentially modulates STAT1 and STAT3 activation in the myocardium exposed to ischemia/reperfusion injury. Am J Cardiol 101:63E–68ECrossRefPubMed
49.
go back to reference Olive M, Mellad JA, Beltran LE, Ma M, Cimato T, Noguchi AC, San H, Childs R, Kovacic JC, Boehm M (2008) p21Cip1 modulates arterial wound repair through the stromal cell-derived factor-1/CXCR4 axis in mice. J Clin Invest 118:2050–2061PubMed Olive M, Mellad JA, Beltran LE, Ma M, Cimato T, Noguchi AC, San H, Childs R, Kovacic JC, Boehm M (2008) p21Cip1 modulates arterial wound repair through the stromal cell-derived factor-1/CXCR4 axis in mice. J Clin Invest 118:2050–2061PubMed
50.
go back to reference Sano S, Itami S, Takeda K et al (1999) Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J 18:4657–4668 30. Welte TCrossRefPubMed Sano S, Itami S, Takeda K et al (1999) Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J 18:4657–4668 30. Welte TCrossRefPubMed
51.
go back to reference Renner E, Puck J, Holland S et al (2004) Autosomal recessive hyperimmunoglobulin E Syndrome: a distinct disease entity. J Pediatr 144:93–99CrossRefPubMed Renner E, Puck J, Holland S et al (2004) Autosomal recessive hyperimmunoglobulin E Syndrome: a distinct disease entity. J Pediatr 144:93–99CrossRefPubMed
52.
go back to reference Minegishi Y, Saito M, Morio T et al (2006) Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 25:745–755CrossRefPubMed Minegishi Y, Saito M, Morio T et al (2006) Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 25:745–755CrossRefPubMed
53.
go back to reference Woellner C, Schaffer A, Puck J (2007) The hyper IgE syndrome and mutations in TYK2. Immunity 26:535CrossRefPubMed Woellner C, Schaffer A, Puck J (2007) The hyper IgE syndrome and mutations in TYK2. Immunity 26:535CrossRefPubMed
Metadata
Title
Pathogenesis of Hyper IgE Syndrome
Authors
Jennifer Heimall
Alexandra Freeman
Steven M. Holland
Publication date
01-02-2010
Publisher
Humana Press Inc
Published in
Clinical Reviews in Allergy & Immunology / Issue 1/2010
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-009-8134-1

Other articles of this Issue 1/2010

Clinical Reviews in Allergy & Immunology 1/2010 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.